JPMorgan lowered the firm’s price target on PTC Therapeutics (PTCT) to $75 from $78 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Cautious Hold Rating on PTC Therapeutics Amid Regulatory Challenges and Pipeline Developments
- Strategic Resilience and Growth Potential: A Buy Rating for PTC Therapeutics Amid Regulatory Challenges
- PTC Therapeutics: Strategic Growth and Market Expansion Justify Buy Rating Amid Regulatory Challenges
- PTC Therapeutics Faces EU Setback on Translarna
- PTC Therapeutics: EC adopts CHMP negative opinion on Translarna